It looks like Abbott is partnering with this company in order to provide the technological expertise to integrate effective cancer biomarkers into their platform for breast cancer diagnostics. (I could be interpreting it wrong!)
"Data will be aligned with a panel of cancer markers from Abbott. Combinations of markers will be selected for further development and integration into Abbott's instrument platforms, used widely in hospitals and clinical laboratories throughout the world."
I suppose you would have to read the whole article in context. It does seem as though this company is in the business of researching, identifying biomarkers and technology integration.
I pose this question to the board, "how does this new Abbott partnership reflect on the licensing agreement with Biocurex? Could Abbott be including recaf as one of the "biomarkers to be aligned with data" from this company. Is the Abbott/Biocurex deal limited to prostate, or can Abbott use recaf technology in breast cancer diagnostics as well? Or would Abbott need to sign a new licensing agreement re:breast cancer? Could this new partnership provide the data from the outside source (or lead to write-ups in medical journals)Bocxman has been anticipating? I welcome as much feedback as possible (points of view), for the benefit of the board!
